Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need

In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Pengfei, Li, Jingxin, Pan, Hongxing, Wu, Yanfei, Zhu, Fengcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851657/
https://www.ncbi.nlm.nih.gov/pubmed/33531462
http://dx.doi.org/10.1038/s41392-021-00481-y
_version_ 1783645672883355648
author Jin, Pengfei
Li, Jingxin
Pan, Hongxing
Wu, Yanfei
Zhu, Fengcai
author_facet Jin, Pengfei
Li, Jingxin
Pan, Hongxing
Wu, Yanfei
Zhu, Fengcai
author_sort Jin, Pengfei
collection PubMed
description In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid large-scale filed efficacy trials and facilitate the approval of vaccine candidates, which is crucial to control COVID-19 pandemic. Several phase 3 efficacy trials of COVID-19 vaccine candidates are under way, which provide opportunities for the determination of COVID-19 correlates of protection. In this paper, we review current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlates of protection and issues related to COVID-19 correlates of protection.
format Online
Article
Text
id pubmed-7851657
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78516572021-02-02 Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need Jin, Pengfei Li, Jingxin Pan, Hongxing Wu, Yanfei Zhu, Fengcai Signal Transduct Target Ther Perspective In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid large-scale filed efficacy trials and facilitate the approval of vaccine candidates, which is crucial to control COVID-19 pandemic. Several phase 3 efficacy trials of COVID-19 vaccine candidates are under way, which provide opportunities for the determination of COVID-19 correlates of protection. In this paper, we review current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlates of protection and issues related to COVID-19 correlates of protection. Nature Publishing Group UK 2021-02-02 /pmc/articles/PMC7851657/ /pubmed/33531462 http://dx.doi.org/10.1038/s41392-021-00481-y Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Perspective
Jin, Pengfei
Li, Jingxin
Pan, Hongxing
Wu, Yanfei
Zhu, Fengcai
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
title Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
title_full Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
title_fullStr Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
title_full_unstemmed Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
title_short Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
title_sort immunological surrogate endpoints of covid-2019 vaccines: the evidence we have versus the evidence we need
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851657/
https://www.ncbi.nlm.nih.gov/pubmed/33531462
http://dx.doi.org/10.1038/s41392-021-00481-y
work_keys_str_mv AT jinpengfei immunologicalsurrogateendpointsofcovid2019vaccinestheevidencewehaveversustheevidenceweneed
AT lijingxin immunologicalsurrogateendpointsofcovid2019vaccinestheevidencewehaveversustheevidenceweneed
AT panhongxing immunologicalsurrogateendpointsofcovid2019vaccinestheevidencewehaveversustheevidenceweneed
AT wuyanfei immunologicalsurrogateendpointsofcovid2019vaccinestheevidencewehaveversustheevidenceweneed
AT zhufengcai immunologicalsurrogateendpointsofcovid2019vaccinestheevidencewehaveversustheevidenceweneed

Ejemplares similares